Reneuron (RENE.L) is a stem cell research company whose focus is on therapies targeting areas of poorly met medical need, including peripheral arterial disease, stroke, and retinal diseases. RENE is currently testing the effects of neural stem cells on spines for neuroregeneration, and is testing the use of fetal stem cells on stroke patients.
A UK company, used as a scientific comparable due to status of trials and disease state.
May 19, 2016
RMi’s closing bell scrutiny: sector roulette
May 18, 2016
RMi’s closing bell scrutiny: along for the momentum ride
May 17, 2016
RegMed’s closing bell: caught in the dilemma of discounted value
May 16, 2016
RegMed’s closing bell: upside actions seem impulsive but, it’s always good to start the week on a positive note
May 13, 2016
RegMed’s closing bell: Friday closed negative after a bad week as volatility continued unabated
May 12, 2016
RegMed’s closing bell: the day’s corollary … there is a notable lack of conviction.
May 10, 2016
RegMed’s closing bell: weakness due to crosscurrents of financial results/earning’s period
May 9, 2016
RegMed’s closing bell: it was time for an upside
May 6, 2016
RegMed’s closing bell: fear is the norm
35 companies, 1 interpreter!
Insight, foresight and recommendation
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors